Skip to main content

Fortrea Holdings Inc Investor Event Transcript, Nov 17, 2026

Fortrea Holdings Inc. (FTRE)

Fortrea CEO Anshul Thakral said demand is picking up across early-phase, biotech and biopharma work, with biotech still a growth driver. The company made a modest backlog adjustment to better reflect the rest-of-life revenue on its contracts. It also closed its Texas site acquisition, which adds a 200-bed facility. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - FTRE 2026-11-17

Dave Windling, Analyst — Jeffries Healthcare Equity Research

All right. She's giving us the thumbs up. Welcome, everybody. I'm Dave Windling with Jeffrey's Healthcare Equity Research. I cover the CRO space. I'm the old gray hair in that business, so I've been around the block a little bit and just love to have the companies in that space in the public domain, for one, and coming to our conference for two. I'm grateful that the Fortria team is here. Anshul Thakral, the company's CEO, for a little over a year now. He's been very, very busy, and Jason Knobloch, who's joined more recently as CFO. Thank you both for being here.

Jason F. Knoblauch, CFO

You bet.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

And thank you to the audience, both in person here and listening for your attention. So, Anshul, let's start on demand. And for you, commercial excellence. So the combination of an environment that is getting better and a commercial focus that you have improved and getting better has driven consistently solid book-to-bills for you. Talk about how you've seen that evolve, how that is manifesting in demand by customer cohort, you know, customer, pharma and biotech, excuse me, and just kind of the robustness and the, you know, call it the completeness of the picture. Sure. Happy to, Dave. First of all, it's nice to see you.

Anshul Thakral, CEO

Thanks for stopping the rain while we walked over from Hotel 1 to Hotel 2. I wish I had that power. Yeah. So look, I think the demand environment, when I met with you, I think it was a year ago or something like that, I started using words like cautiously optimistic. I think I'm getting ready to drop the word cautiously off as a identifier there. I think we're getting into the middle of demand recovery here. What happened? We saw early phase work, phase one work pick up the fastest. That's where decision making can be quickest. So sometime in middle of 2025, we started seeing the demand for healthy volunteer studies in phase ones really pick up. Then we started seeing demand from biotech companies pick up as funding environment got better. And I don't look at funding month to month. I try to look at it more of a trend line like you do. And as that environment really started getting better, I'd say probably November of last year, going into early part of this year, we saw biotech demand starting to pick up. And now, over the last several months, we've really seen biopharma demand also pick up. I think once the first company negotiated its agreements with the U.S. government, all of a sudden R&D pipelines started to move again at what I would call getting closer to a normal clip. And so we're sitting here now towards the end of 2026, and I feel comfortable that in the segments of the market that I look at, one being early phase, another being biotech, and another one being biopharma, we're seeing demand pick up across all three. I think biotech remains a growth driver in terms of percentage of growth. It seems to be accelerating and remains a growth driver. But I think 2027 is going to be an interesting year for the industry. Excellent.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah, that's great. So while we're on large pharma versus biotech. And this is going to, I'm probably setting your early phase business aside, but what's the relative size of opportunity? So thinking about, you know, spending the sales force time, what's the payoff for the time in terms of size?

Anshul Thakral, CEO

Sure. I think, look, from a market perspective, right, the vast amount of dollars that get spent by what I call biopharma, call it the top 30 or so company. But growth right now and innovation, I see a lot of that in biotech or the small to midsize companies. I would say right now I've got our time disproportionately focused in biotech, the reason being in biopharma, these are long sales cycles. These are partnership agreements and partnership cycles, and they take time. So the sales effort there looks different than a traditional RFP prosecution. What it looks like is building relationships, getting invited to partnerships, working a partnership construct, winning a partnership. And then it's really up to the operations team in putting the right proposals together, executing good work. That's what yields repeat business within biopharma. In biotech, that requires a lot more hand-to-hand sales interaction. So if you're asking me where am I putting my sales team and my commercial team's time, it's a little disproportionate. It's disproportionate not because one is a priority versus another. One requires a different approach than the other.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

In that, in so much as your phrase that you use to focus the conversation on commercial excellence, in so much as that I'm sure is honing focus, maybe top grading, and expanding a wider net, how much of the market are you seeing, do you think, and how much still upside do you have from seeing more of the opportunities?

Anshul Thakral, CEO

So I think that's a great question. I appreciate it. And I think commercial excellence is not just about top grading, but top grading has been a big part of what I've done over the past 15 some odd months. But the big part at Fortria has been that it's not a sales rep who is necessarily winning a deal. It takes folks in operations, folks in finance, if it's an FSP deal, folks in HR often, and you've got to be able to bring a much wider talent base together to win a deal. So that's been a lot of the focus in commercial excellence. But to answer your question specifically, it depends a little bit on the market. I would say in the world of biotech, we've got a lot of opportunity here. We're probably seeing somewhere on the order of 25 to 30 percent of RFPs out there. I'd like to be seeing a lot more than that, and that comes with continuing to expand our reach. In the world of biopharma, as I mentioned to you last time we talked, you know, we've got our platform, big pharma clients, that we've had decade-long relationships with, and they're going well. But now, for the first time, even since the spin or even before the spin, we're being invited to biopharma partnerships that we weren't normally invited to. We're now getting seed at the table, and so our aperture is really starting to grow. There isn't a biopharma company in the top 30 that we don't have some level of connectivity with, but now we're getting invited to large partnership refreshes that are de novo for us in companies that we've not worked, one of which we won recently in the last few months, and that's, again, part of what we've been trying to achieve in commercial excellence. In terms of the last part of your question, how much more room is there, I think we're just getting started, Dave. Okay.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

So your mention of the wind, that's where I was going to go next. On these partnerships, I'll let you start with the win. If there's anything to expand or add on there, then I think you also, to my good friend Eric, you said six of the top 12 are ongoing refreshes. Six of 12 all in the top 30, I believe is how you described it, that those are ongoing refreshes. Maybe give us a flavor for when those land, how they're going, things like that. Happy to.

Anshul Thakral, CEO

So I'll start with the second part of the question. So what I said to Eric was six to 12 such refreshes. Why am I giving myself a range? Some of them, I don't know if they're real or not, or if they're just a stocking horse or pricing. So I try to be more realistic in terms of where they're really making changes. And remember, any one of these top 30 companies, they're not so simplistic that they look at only one outsourcing model and do only one sort of refresh. These are complex, nuanced areas. Some are only doing it in FSP. Some are only doing it in a therapeutic area. Some are only doing it in an early phase across the board. But the point I had made in a conversation earlier on around earnings was we are now invited to a handful of these refreshes that are de novo to us. These are new clients to us that we've not worked with in the past. One or two of them we haven't been successful in already. One of them we were wildly successful in. We're actually quite excited about big pharma company. Two phase threes have already been awarded to us. Now comes the hard work of delivering against them and continuing to build our platform there. But we still have several that are outstanding, and these span everywhere, everything between a partnership on clinical pharmacology work, partnership in clinical FSO, in biometrics FSP, or clinical FSP, or some combination thereof. The thing that I'm most focused on right now is what did we do in the last 15 months to position ourselves to get there? How have we been working in our operations team to change perceptions and reputations so that clinical operations leaders are going to procure them and saying, I want to include Fortria? That's happened. That's an accomplishment. That I feel proud about. Now we've got to win some of these, deliver against them, and continue on the journey of growth.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah, that's very interesting. So to clarify for me in the audience, the one wildly successful is this same one that you talked about as a win in the third quarter?

Anshul Thakral, CEO

One in the third quarter. We just got awarded two phase threes. We're just getting ready to kick that off. We think we're just at the beginning of that journey. As I've said to you in the past, I don't think in big pharma anything happens quickly. These things mature over time. If we do our job right, this can become an important piece of our backlog going forward. Yeah.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

While we're on the subject, you also had a refresh for a pretty important incumbency for you. How satisfied are you with how that concluded?

Anshul Thakral, CEO

I just want to check the time, so we're 10 minutes into this question. You made it 10 minutes.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

I think I made it 11 minutes.

Anshul Thakral, CEO

I bet Cassidy was going to be a little shorter than that. I'm happy with where we are. I'm very comfortable with our largest pharma client. I actually try to be personally involved in all of our top 10 clients from both a backlog and a revenue standpoint. This one, I'm very personally involved. I'm comfortable with where we are. Our team continues progressing. We've recently received awards from them that we're excited about, and we continue to march down a journey. Okay.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

One phrase that you've used while we're on this partnership topic I want to explore is the partner of choice for evidence generation. And while I understand that that's not exactly unique. Um, phrase. It is one that I think you're using in a way that I don't hear your peers using. And so it feels like a point of differentiation that you're trying to emphasize. I wanted to allow you to explore that.

Anshul Thakral, CEO

Thanks, Dave. Um, it is a word that gets used a lot. It's nothing special or coined for phraseology for me, but it is a way for me to demonstrate to investors, to customers, but probably most importantly to employees, A concept of focus. So I get asked questions around, well, what's next? Where are you going to go? What's your capital deployment look like? What does M&A look like? Where are you guys going to grow? Where are you guys going to invest? And what I'm trying to articulate with being focused in evidence generation is exactly that word focus. We're going to stay good at what we are good at. We help generate data that supports clinical trials. Now that can come in the form of healthy volunteers being done in a phase one. That can come in the form of a clinical trial being run in China or some other part of the world. That can come in the form of chart reviews, phase three Bs, post-approval work, market access work. But there has to be some theme to every company where we are focused. So what does that imply? Our intention isn't to go become a data provider. Our intention isn't to become an IT company. Our intention isn't to go back into the world of central labs, for example. Our job is to support both biotech and biopharma clients in generating evidence to support their clinical work. That can range from... An eight-patient healthy volunteer trial. To a 2,000-patient liver disease trial being conducted in 61 countries, to an AI-insisted chart review of post-approval studies in the future. But it's about focus and keeping us focused at being good at what we are.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah. Okay. Got it. Yeah, I appreciate that. Let's move on and try to put Jason to work here a little bit. Let's ask a backlog question. So, you just did a backlog review, and the result of that was a modest adjustment to your backlog. So, the remaining backlog, I believe you would say, better represents the rest-of-life revenue on the contracts that you have. How does that... Kind of help your near to medium term planning, and does it give you better confidence in the conversion rates of what is now remaining in the backlog?

Jason F. Knoblauch, CFO

Yeah, happy to take that one. So we did, during the quarter, do a detailed review of our backlog positions, and as I alluded to on our earnings call and in the Q&A thereafter, you know, look, in this world of drug development, there's often a lot of different situations that can create some ambiguity in the status of a study or elements of a study. And what we're addressing with this backlog adjustment is getting our stated position, our stated value. To what we believe is the best estimate of full future life revenue on the studies that we have in hand. There's a lot of situations where, you know, trial will often go on pause, and, you know, we're not exactly certain, the customer's often not exactly certain how things are going to play out. Often there's regulatory reviews involved and other elements at play. And so there can be this period of latency that does exist between, you know, when some of these developments start to occur and when things actually get codified in an amended contract. So we believe this gets us to the right spot. It doesn't impact our, you know, the near-term and medium-term revenue planning that we do. If something goes on pause, we're already, you know, appropriately accounting for that in our revenue assessment. So this just gets kind of the stated value where it needs to be. Got it. But as you alluded to at the end there, you know, all else equal and There's going to be variations from quarter to quarter, but all else equal, we would expect that at the aggregate level, you would see some improvement in that conversion rate.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Okay, got it. And Jason, on the call at roughly $560 million, was that a combination of pass-throughs and direct fee, or was that heavy on the pass-through side, or what was composition of that?

Jason F. Knoblauch, CFO

Yeah, no, it's both, right, because our backlog, our revenue includes direct fees and pass-throughs. And there was certainly a heavy element of both of those parts of the feature structure.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

And then while we're on backlog, we've tried to, I think, somewhat belatedly get a better understanding of RPO and with all the different, you know, the slightly different backlog policies across the companies that can create, you know, differences between backlog and RPO. So what are Fort Rhea's biggest... There's gap differences between what is in backlog and what's in RPO.

Jason F. Knoblauch, CFO

Yeah, sure. And I give you some kudos and props for some of that work you've been doing. I think when you look at – so there are different measures. RPO is kind of a gap measure that came out of the 606 accounting a number of years ago. There are big differences. So RPO is ultimately trying to reflect long-term contracts where the company has an obligation to perform for a long period of time. So with that, the differences are going to be things like our FSP book of business are not going to be an RPO. Things like our CPS early phase studies are not going to be an RPO because those are short duration. Contracts that we have in hand. There are also elements of our FSO portfolio that do not meet the criteria. So you've got kind of this, you know, whittling down waterfall from backlog to that RPO measure. And because of that, you know, we're going to continue to, you know, report on our backlog. We're going to continue to talk about our backlog and our net bookings. We think those continue to be important measures for our revenue planning.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Okay. I'm glad I asked because part of that answer I wouldn't have anticipated. The CPS perhaps makes, you know, that makes sense. I didn't know that. Let's move to mix. Anshul, probably predating your time, actually, I would have gotten a rough sketch of Fortria's revenue mix as something like 40% FSO, 40% FSP, and 20% CPS. You've, you're pursuing FSO more aggressively. You've acquired in FS, I'm sorry, you've acquired in CPS. How does that mix look today?

Anshul Thakral, CEO

Well, I don't know what numbers predate me or don't predate me, but we haven't been talking specific numbers within any particular business. We're not reporting out business unit level financials. I think what I have said in the past is if you think about in order of increasing order of revenue, CPS, FSP, then FSO. FSO is the biggest lion's share of what we do. And I'm being very targeted and strategic in FSP, and we see near-term growth opportunities in biotech FSO and CPS, and we're capitalizing on them. And we've really been capitalizing in the last five quarters, so that should be enough to draw some math.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah. As you avail yourselves of those FSOs, opportunities. How would you describe bid margin versus current margin?

Anshul Thakral, CEO

Sure. I think, look, we don't disclose specifics of bid margin or current margin because. You'd be talking to customers about what margins you're making on that work. I think it goes without saying, though, if we think about our value creation levers, right, and we're on a margin journey, and you think about our value creation levers, certainly one value creation lever is bid margin, and bid margin tends to be higher, not giving Fortria's numbers, tends to be higher with smaller companies and bigger companies because of scale, tends to be higher in FSO versus FSC. I see FSP because of your offering a differentiated service versus an undifferentiated service. So you can draw your analogies on that. So that is the first level. Now, as a company that was for a long time a business unit within a business unit of a wonderful company called LabCorp, it is possible that it was not being operated with the same level of rigor that someone like Jason and I are going to want to operate this company at. So that would imply that the differential between bid margin and delivery margin will continue to get smaller and smaller over time. That's as many breadcrumbs as I can throw out there.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah, I like that last one. Thank you. As you described, you just got through saying CPS is the smallest of those three categories of revenue, yet for Fortria, CPS is more important than it is for a number of your peers. I mean, you are making a bigger investment, a bigger bet in CPS. Let's talk about... How you see that strategically setting you, I mean, is that a means to an end to get the phase two, three work downstream? Is CPS a more profitable business than the overall business itself on a standalone basis?

Anshul Thakral, CEO

Talk about how it fits strategically. Great question. I appreciate the question. So the first part of your question is an assumption that CPS is a bigger portion of our revenues than it is for the next set of competitors. You know, Icon and Paracel are the other ones that have at-scale CPS businesses. Everybody else's are somewhat sub-scale. You are absolutely correct in that assumption. So it is a bigger portion. But it's not a means to an end by any means because it's hard work. What I like about our CPS business is a few things. One, I think we have one of the highest quality products. I think we're a market leader. If we're not number one, then we're top two or three in any given pharma company's mind when it comes to that product as far as full-service CROs that do that work or concern. So our right to win is higher. It opens up an aperture for me in certain customers, whether it be biotech or biopharma, where I don't have GCD work. And when we deliver really good, really well in this business, it does not guarantee us work in our main business. But what it does do is open up doors. It allows us to have the right to bid on future work because we're building longstanding client relationships. And the Venn diagram of our customers in CPS and GCD doesn't overlap as much as you think. So if you continue to do really well, it will, over time, create and open up the aperture to new clients and customers. Beyond that, Dave, it's a great business. We've been in for multiple decades. It's a very high science business. And if you plan not for a quarter, but if you plan for the long term and you plan for a decade out, this is a business in where we get to see early science, and we get to see more than our fair share of early science, and we get to develop expertise in therapeutic areas that we may not necessarily develop in the later phase. So it's not about a means to an ends. I think this is a unique business. I think we have the right to win. I think we're a market leader, and we deliver a very high-quality product. Everything else is going to be a natural, positive byproduct for us.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

You, you've had, so you bought the, the worldwide, um, Texas, I think it's two, two sites, two facilities, um, brings with it capacity on the bedside and some lab capabilities. How much, you didn't really talk in specifics about how much revenue it brings with it. You talked about folding it into your sales engine, but how, how much kind of existing business does it bring?

Anshul Thakral, CEO

So I would say this. Don't get into disclosing specific business unit numbers, and we agreed with the seller we wouldn't be disclosing specifics here, but I would tell you that one of the reasons worldwide clinical trials, and I have a lot of respect for Jason and Alistair, and with their owners, Colbrook, decided to divest here, is they weren't able to achieve scale, and they had focus and priorities elsewhere, whereas we are already an at-scale player. So our ability to drive bed night utilization or revenues per bed night is higher than their ability to do the same. So my expectation will be that it's not about the meaningfulness of the revenues that are coming with it. It's about what can we drive in this business given the size and scale we have. And given the fact that more often than not, we've talked about this multiple times, we're getting high volumes of work where we're having to use external sites. And now we have a 200-bed site readily available. We can actually create a network within Texas of 300 beds across our two sites with a couple of hours' drive. So our ability to drive utilization of this asset far supersedes its prior owner's ability to drive utilization. That's the value creation opportunity. That's the principle of this acquisition.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

I'm at time. I don't see anybody in the back, so I'm going to squeeze in one more. Go for it. Always do. Your pass-through, so I think both a function of your efforts to try to focus on FSO, but also in a separate bucket, as we've discussed, the phase one business has had this unique kind of large package deals that you've had to send to places like this worldwide site that creates a pass-through dynamic. To what extent does this worldwide deal alleviate some of the pass-through intensity in your revenue stream? How should we be thinking about modeling this as you go forward?

Jason F. Knoblauch, CFO

Yeah, look, I think I'll just, you know, sort of re-underscore what Anshul mentioned, which is that, you know, with the scale that we have in that business, we already today in our CPS footprint have a, you know, a meaningful amount of pass-through volume. Some of it is going to a lab. Some of it's going to other CRU units that can help service some of these larger patient studies that we're getting contracted to lead. And we believe we're going to be able to start to sort of reallocate that into the assets that we acquired in Texas in good fashion. So, you know, putting aside any other, you know, mixed dynamics in our overall portfolio, this will be some tailwind for us.

Anshul Thakral, CEO

Okay. Within the first week of closing the deal, there's small numbers, but one of the things CEOs do is always gloat over others' accomplishments. Within the first week, we actually were able to put a new study into the lab and several new studies into the clinic, and that was all within the first week of closing the deal. There's small numbers yet, but...

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Yeah.

Anshul Thakral, CEO

We're very excited about what we're going to be able to do.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Does that lab have capacity to take a decent amount of work? It does.

Anshul Thakral, CEO

We feel very comfortable that that lab is going to be able to service our entire network in the U.S.

Dave Windling, Analyst — Jeffries Healthcare Equity Research

Okay. All right. Fantastic. I went past time. I wasn't Southwest. Thank you very much for your attention.